BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• Press Releases

  Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

  May 4, 2026

   · 

  14 min read
• Press Releases

  CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

  May 4, 2026

   · 

  1 min read
• Press Releases

  Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

  May 4, 2026

   · 

  1 min read
• Press Releases

  NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

  May 4, 2026

   · 

  2 min read
• Press Releases

  Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

  May 4, 2026

   · 

  3 min read
• Press Releases

  Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

  May 4, 2026

   · 

  3 min read
• Press Releases

  Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

  May 4, 2026

   · 

  1 min read
• Press Releases

  ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

  May 4, 2026

   · 

  4 min read
• Press Releases

  Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

  May 4, 2026

   · 

  8 min read
• Press Releases

  Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

  May 4, 2026

   · 

  12 min read